The Short Answer — What Current Evidence Shows
After 52 weeks of treatment, over 62% of participants with a serious form of liver inflammation saw it resolve in a dedicated clinical trial of tirzepatide for liver disease. This suggests Mounjaro's liver benefits are not merely short-term or superficial — they reflect genuine disease modification.
The longer trajectory — beyond 12 months — is less completely characterised than for semaglutide, but the available data is consistently positive. The mechanisms of tirzepatide's liver benefit (dual GLP-1/GIP receptor activation, significant weight loss, improved insulin sensitivity) are expected to produce sustained benefit with continued use, mirroring the pattern observed with semaglutide.
The SURMOUNT Trials — What Long-Term Data Shows
Mounjaro's long-term safety and efficacy has been evaluated primarily through the SURMOUNT clinical trial program. Across five SURMOUNT trials involving thousands of patients over 72–84 weeks:
Weight loss: Average weight loss of 20–22.5% at the maximum maintenance dose over 72 weeks — the greatest sustained weight reduction achieved by any approved pharmacotherapy.
Liver enzyme trends: In patients with metabolically driven liver enzyme elevations, ALT and AST levels consistently improved alongside weight loss. No clinically significant hepatotoxicity was identified in any SURMOUNT trial.
Safety profile: The most common side effects were gastrointestinal — nausea, vomiting, diarrhoea — predominantly during dose escalation. The first SURMOUNT study demonstrated that, at the maximum maintenance dose over 72 weeks, the average weight loss was 22.5%, and the study concluded there were no major safety concerns, with the most common side effects being mild to moderate gastrointestinal events.
The SYNERGY-NASH Trial — The Definitive Liver Data
The SYNERGY-NASH trial is a dedicated phase 3 trial of tirzepatide specifically in patients with MASH, which completed enrolment in 2025 with results expected in 2026. This will be the most definitive dataset on Mounjaro's long-term effects on the liver.
Based on phase 2 data and the established mechanisms of tirzepatide, the expected findings from SYNERGY-NASH are:
- MASH resolution rates comparable to or exceeding those seen with semaglutide in the ESSENCE trial
- Fibrosis stage improvement in a meaningful proportion of patients
- Liver enzyme normalisation rates reflecting the magnitude of weight loss and metabolic improvement
- A favourable long-term hepatic safety profile
If SYNERGY-NASH confirms these expectations, Mounjaro is likely to become the second GLP-1 medication to receive TGA approval specifically for MASH treatment in Australia — and potentially the preferred option given its superior weight loss profile.
What Long-Term Mounjaro Use Means for the Liver
Based on current evidence, the expected liver trajectory for a patient taking Mounjaro long-term is:
Year 1: Significant liver fat reduction (30–40% reduction in hepatic fat content is consistent with phase 2 data). Liver enzyme normalisation. In patients with MASH, significant reduction in liver inflammation. Some fibrosis improvement beginning.
Year 2: Sustained liver fat reduction. Continued fibrosis improvement in responding patients. For patients with F2–F3 fibrosis, possible downstaging to F1 or F0. Elastography (kPa) improvements measurable.
Beyond Year 2: The liver benefits of significant, sustained weight loss are cumulative. Patients who maintain weight loss on Mounjaro are expected to show continued liver health improvement consistent with the metabolic normalisation being achieved.
The critical caveat: if Mounjaro is stopped and weight is regained, liver fat will increase and MASLD may return or worsen. The liver benefit is sustained by the medication and the associated weight loss — it is not a permanent cure.
What Is Not Yet Known
Tirzepatide is a newer medication than semaglutide. The following questions remain partially or fully unanswered:
Beyond 84 weeks: The longest completed SURMOUNT trial runs to 84 weeks. Very long-term (5+ year) hepatic outcome data — cirrhosis prevention, liver transplantation rates, liver cancer incidence — does not yet exist for tirzepatide specifically.
Head-to-head with semaglutide on liver histology: The SURMOUNT-5 trial compared tirzepatide and semaglutide for weight loss and found tirzepatide superior. But this was weight loss — not liver histology. Head-to-head liver biopsy comparison data does not yet exist.
Whether the liver benefit outlasts treatment: SURMOUNT-4 data on treatment cessation showed significant weight regain after stopping tirzepatide. The corresponding liver effects of weight regain are expected to be unfavourable — but the exact timeline and magnitude has not been directly studied.
Monitoring Recommendations for Long-Term Mounjaro Use
For patients taking Mounjaro long-term, the following liver monitoring schedule is appropriate:
Before starting: Full liver function panel, FIB-4 calculation. Liver elastography if FIB-4 is indeterminate.
At 3 months: Repeat ALT/AST to assess early enzyme changes.
At 12 months: Repeat full liver function panel and FIB-4. If baseline elastography was performed, consider repeat to assess response.
Annually thereafter: Liver function panel. For patients with known MASLD or MASH, annual or biennial elastography to track fibrosis trajectory.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
What are the long-term effects of Mounjaro on the liver?
Current evidence from trials up to 84 weeks shows consistent liver benefit — reduced liver fat, improved liver enzymes, and in a dedicated liver disease trial, MASH resolution in over 62% of patients. No clinically significant long-term liver toxicity has been identified.
What are the long term effects of Mounjaro on the liver?
Trials up to 84 weeks show liver fat reduction, enzyme normalisation, and MASH resolution in over 62% of patients in dedicated liver disease studies. Benefits depend on continued treatment and sustained weight loss — stopping Mounjaro and regaining weight typically reverses liver gains.
Can Mounjaro cause liver damage long-term?
No long-term liver damage has been identified in clinical trials. The predominant long-term hepatic effect is liver improvement, not harm. As with all medications, rare adverse events are possible, and monitoring is appropriate.
Will the liver benefits of Mounjaro persist permanently?
The liver benefits are associated with the weight loss and metabolic improvements achieved on Mounjaro. If the medication is stopped and weight is regained, liver fat and enzyme levels are likely to worsen. The benefit is sustained by continued treatment.
When will the SYNERGY-NASH results be published?
The SYNERGY-NASH trial completed enrolment in 2025 with results expected in 2026. These will provide the most definitive data on Mounjaro's efficacy specifically for MASH treatment.
Is Mounjaro approved to treat fatty liver in Australia?
Not yet specifically. Wegovy (semaglutide) received TGA provisional approval for MASH in April 2026. Mounjaro does not yet have a specific liver disease indication in Australia — pending SYNERGY-NASH results.
Related reading
Sources: SURMOUNT trial program; SYNERGY-NASH trial (2025); NIH LiverTox tirzepatide (2025); Superdrug clinical review (2026); SURPASS-5 NEJM (May 2025).
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.